Hypersensitivity Types and Anaphylaxis Response
Key Points
- Hypersensitivity reactions are exaggerated immune responses to antigens that can damage healthy tissue.
- Allergic responses are hypersensitivity reactions to allergens that are usually harmless to most people.
- Type I reactions can progress rapidly to anaphylaxis with airway and circulation compromise.
- Immediate recognition and epinephrine-first treatment are core nursing safety priorities in severe reactions.
Pathophysiology
Hypersensitivity occurs when immune activation is excessive, prolonged, or directed at inappropriate targets. Instead of resolving threat safely, inflammatory mediators and immune-cell activity produce tissue injury and systemic symptoms.
Mechanisms vary by reaction type, including IgE-mediated mediator release, antibody-mediated cytotoxicity, immune-complex deposition, and delayed T-cell responses. Clinical impact ranges from mild discomfort to life-threatening cardiopulmonary compromise.
Common allergen exposure routes include inhalation, direct contact, and ingestion, and the clinical response pattern varies by host susceptibility and prior sensitization.
Allergic-Response Sequence
| Physiologic step | Core event |
|---|---|
| Antigen capture | APCs process allergen and present antigen fragments to T cells |
| Helper-T activation | Cytokine signaling activates B-cell and mast-cell pathways |
| B-cell antibody shift | B cells generate allergen-specific antibodies, especially IgE in immediate allergy pathways |
| Sensitization | IgE binds mast-cell and basophil receptors |
| Re-exposure | Allergen cross-links receptor-bound IgE |
| Mediator release | Histamine, leukotrienes, prostaglandins, and related mediators are released |
| Immediate phase | Vasodilation, capillary leak, itch, bronchoconstriction, mucus secretion |
| Late phase | Eosinophil-rich inflammatory infiltration with prolonged tissue symptoms |
Classification
- Type I (Immediate): IgE-mediated mast-cell/basophil degranulation; may cause urticaria, bronchospasm, rhinitis, asthma, and anaphylaxis.
- Type II (Cytotoxic): IgG/IgM against cell-surface targets with complement/phagocytic injury (for example autoimmune hemolytic anemia and immune thrombocytopenia).
- Type III (Immune Complex): Soluble antigen-antibody complex deposition with complement activation and neutrophil-mediated inflammation (for example serum sickness and selected vasculitic/glomerular pathways).
- Type IV (Delayed): T-cell-mediated inflammatory injury that appears later (often 1-3 days), including contact hypersensitivity and granulomatous patterns.
Immunoglobulins in Allergy Context
- Major immunoglobulin classes: IgG, IgA, IgM, IgD, and IgE.
- IgE is the key immunoglobulin in immediate allergic disease pathways.
- Atopy is the inherited tendency toward IgE-mediated disorders (for example allergic rhinitis, asthma, atopic dermatitis).
Chemical Mediators
- Primary-phase mediators: histamine, eosinophil chemotactic factors, platelet-activating factors, and prostaglandins.
- Secondary-phase mediators: leukotrienes, bradykinin, and serotonin.
- Histamine is typically an early dominant mediator and contributes to erythema, edema/wheal, pruritus, bronchospasm, and secretory symptoms.
- Leukotrienes are potent bronchoconstrictors and can produce stronger sustained airway effects than histamine.
Nursing Assessment
NCLEX Focus
Prioritize airway, breathing, and circulation signs first when severe allergic symptoms evolve quickly.
- Assess for early allergic findings such as itching, sneezing, hives, congestion, and rhinorrhea.
- Assess for anaphylaxis red flags: dyspnea, bronchoconstriction, angioedema (especially around eyes, lips, and throat), generalized urticaria, and airway swelling.
- Assess for escalating severe-reaction cues, including apprehension or a sense of impending doom.
- Monitor for hemodynamic compromise including widespread vasodilation and reduced perfusion.
- Trend vital signs and respiratory effort continuously during acute reactions.
- Document trigger exposure pattern, symptom timing, severity, prior treatment, and response to interventions.
- Include focused eyes/ears/nose/throat/chest/skin review for multisystem symptom mapping.
Diagnostics and Laboratory Values
- CBC with differential
- Eosinophil measurement (blood or selected secretion-based sampling)
- Total serum IgE
- Skin testing (intradermal or superficial panels) with wheal-and-flare interpretation
- Additional inflammation markers may be used in selected autoimmune/inflammatory differential pathways
Safety During Allergy Testing
- Combine skin-test findings with history, exam, and laboratory data before confirming diagnosis.
- Avoid routine testing during active bronchospasm or unstable respiratory status.
- Use lower-risk scratch/prick methods before deeper testing approaches when indicated.
- Keep emergency-response equipment immediately available for potential systemic reactions.
Nursing Interventions
- Stay with the client and initiate continuous monitoring during suspected anaphylaxis.
- Stabilize or support airway and administer supplemental oxygen as needed.
- Administer intramuscular epinephrine (1:1000) first line at 0.3-0.5 mL as prescribed.
- Administer adjunct therapies (antihistamines, beta-agonist such as albuterol, corticosteroids) per orders.
- Prepare additional supportive measures, including IV fluids, based on evolving instability.
- Educate client/family on trigger avoidance, emergency action planning, and epinephrine auto-injector use when indicated.
- If a medication-triggered reaction is suspected, stop the offending medication immediately and escalate.
- For topical-trigger reactions, remove residue and cleanse affected skin promptly.
- Distinguish likely side effect versus true hypersensitivity by assessing symptom type, timing, and prior exposure history.
- Document reaction onset, manifestations, severity, and intervention response clearly in the clinical record.
- For confirmed or suspected medication allergy, add formal allergy documentation and teach cross-reactive drug-class risk.
- Reinforce emergency preparedness for high-risk patients (for example carrying epinephrine auto-injector and medical-alert identification).
Time-Critical Emergency
Delayed treatment of anaphylaxis can rapidly progress to airway obstruction, cardiovascular collapse, and death.
Pharmacology
| Drug Class | Examples | Key Nursing Considerations |
|---|---|---|
| Hypersensitivity Types And Anaphylaxis Response (epinephrine) | IM epinephrine 1:1000 | First-line treatment in anaphylaxis; give promptly. |
| Hypersensitivity Types And Anaphylaxis Response (antihistamines) | class-based agents | Adjunct symptom control for pruritus and urticaria. |
| corticosteroids | class-based agents | Reduce inflammation and risk of delayed recurrence. |
Clinical Judgment Application
Clinical Scenario
A client develops generalized itching, facial swelling, wheezing, and worsening dyspnea minutes after exposure to a known allergen.
- Recognize Cues: Rapid multisystem allergic findings with airway risk.
- Analyze Cues: Type I hypersensitivity has escalated to probable anaphylaxis.
- Prioritize Hypotheses: Highest priority is impending airway compromise and circulatory instability.
- Generate Solutions: Immediate epinephrine-first emergency pathway with airway and oxygen support.
- Take Action: Administer epinephrine, monitor continuously, and implement ordered adjunct therapies.
- Evaluate Outcomes: Improved breathing, reduced edema, and stabilized perfusion parameters.
Related Concepts
- anaphylaxis - Severe Type I reaction with urgent airway and circulation threats.
- Hypersensitivity Types And Anaphylaxis Response - Prevention strategy for known trigger exposure.
- systemic-lupus-erythematosus - Autoimmune/immune-complex disease context relevant to hypersensitivity mechanisms.
- rheumatoid-arthritis-autoimmune-joint-disease - Chronic autoimmune inflammatory disease linked to hypersensitivity mechanisms.
- medication-administration-safety-measures - Medication safety processes during emergency drug delivery.
Self-Check
- Which features distinguish a mild allergic reaction from evolving anaphylaxis?
- Why is intramuscular epinephrine prioritized before adjunct medications in severe reactions?
- How do Type II, III, IV, and V mechanisms differ from Type I immediate hypersensitivity?